Oxford BioDynamics Fiscal 2019 Revenues Down 24 Percent

Dec 11, 2019

|

NEW YORK — Oxford BioDynamics reported on Wednesday a 24 percent drop in revenues for its fiscal year 2019 amid a decline in revenues generated in the US.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

To Keep Up

SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

On the Rise in the City

The New York Times reports that a new viral variant of concern has been identified in New York City.

Nature Studies Present Single-Cell Map of Cell Cycle, Approach Identifies Cancer Treatment Resistance Pathways, More

In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.

COVAX's First Shipment

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

Featured White Papers

Five Translational Insights Key to a Successful First-in-Human (FIH) Study: Metabolite-Based Biomarker Discovery and Validation

Circulating Protein Biomarkers are a Promising Avenue for Predicting Patient Response to Cancer Immunotherapies

Serum Protein Signatures as a Non-Invasive Tool for Monitoring Nonalcoholic Steatohepatitis (NASH)

White Paper: Using Single-Cell Multiomics to Reveal New Insights Into Uveal Melanoma Evolution and Therapeutic Resistance

Mar

17

Featured Webinar

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar

23

Featured Webinar

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar

24

Featured Webinar

Single-Cell Analysis and Genome Editing in Preclinical Disease Modeling: Detailed Insights into Leukemia Lineage

This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.

Mar

25

Featured Webinar

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

Menu

Oxford BioDynamics Fiscal 2019 Revenues Down 24 Percent

To read the full story....

Breaking News

Personalis Q4 Revenues up 11 Percent

Natera Revenues Grow 35 Percent in Q4

Berkeley Lights Q4 Revenues Rise 31 Percent

NantHealth Q4 Revenues Flat From Year Ago

GenMark Diagnostics Q4 Revenues Rise 84 Percent on MDx Sales

Luminex Shares Surge on Rumor of Acquisition by DiaSorin

The Scan

To Keep Up

On the Rise in the City

Nature Studies Present Single-Cell Map of Cell Cycle, Approach Identifies Cancer Treatment Resistance Pathways, More

COVAX's First Shipment

Featured White Papers

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

Single-Cell Analysis and Genome Editing in Preclinical Disease Modeling: Detailed Insights into Leukemia Lineage

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

What's Popular?

Crown Bioscience, Cambridge Quantum Computing Partner on Cancer Biomarker Discovery

Sponsorships